Metabolic acidosis during the relapse treatment of idiopathic intracranial hypertension
Yıl: 2023 Cilt: 25 Sayı: 2 Sayfa Aralığı: 107 - 110 Metin Dili: İngilizce DOI: 10.14744/agri.2021.05025 İndeks Tarihi: 30-05-2023
Metabolic acidosis during the relapse treatment of idiopathic intracranial hypertension
Öz: We herein present a 40-year-old female physician who was diagnosed with idiopathic intracranial hypertension (IIH) 4 years ago. In the last years, the patient was in remission without any medications. Since the onset of COVID-19 pandemic, she has been stressfully working in the high-risk area, therefore using personal protective equipment (N95 mask, protective clothing, goggles, and protective cap) during the day for extended periods. Her headaches recurred and the patient was diagnosed with a relapse of IIH; acetazolamide and afterward topiramate were initiated, with diet treatment. Symptomatic metabolic acidosis, which is otherwise a rare side effect of the IIH treatment and not seen in her first attack even with higher doses, developed during the follow-up, presenting with shortness of breath and chest tightening. The emerging problems of IIH diagnosis and management during the COVID-19 pandemic will be discussed.
Anahtar Kelime: İdiyopatik intrakraniyal hipertansiyon relaps tedavisi sırasında metabolik asidoz
Öz: Dört yıl önce idiyopatik intrakraniyal hipertansiyon (İİH) tanısı alan, 40 yaşında bir kadın hekim hasta, son yıllarda herhangi bir ilaç kullanmadan remisyonda takip edilmekteydi. Koronavirüs hastalığı (COVID-19) salgınının başlangıcından bu yana yüksek riskli alanda ve stres altında çalışan hasta, gün boyunca uzun süreler kişisel koruyucu ekipman (N95 maskesi, koruyucu giysi, gözlük ve koruyucu başlık) kullanıyordu. Bu süreçte hastanın baş ağrıları tekrar ortaya çıktı ve İİH nüksü nedeniyle asetazolamid, ardından topiramat ve diyet tedavisi başlandı. İİH tedavisi sırasında, tedavinin çok nadir bir yan etkisi olan ve hastanın ilk atağında daha yüksek dozlarda tedavi altında olmasına karşın görülmeyen semptomatik metabolik asidoz, nefes darlığı ve göğüs sıkışma hissi ile karakterize bulgu ve semptomlar ortaya çıktı. Burada, COVID-19 salgını sırasında İİH tanısı ve yönetiminde ortaya çıkan sorunlar tartışılacaktır.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Olgu Sunumu Erişim Türü: Erişime Açık
- 1. Markey KA, Mollan SP, Jensen RH, Sinclair AJ. Understanding idiopathic intracranial hypertension: Mechanisms, management, and future directions. Lancet Neurol 2016;15:78–91.
- 2. Horton JC. Acetazolamide for pseudotumor cerebri: Evidence from the NORDIC trial. JAMA 2014;311:1618–9. [CrossRef]
- 3. NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee; Wall M, McDermott MP, Kieburtz KD, Corbett JJ, Feldon SE, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: The idiopathic intracranial hypertension treatment trial. JAMA 2014;311:1641–51. [CrossRef]
- 4. Hoffmann J, Mollan SP, Paemeleire K, Lampl C, Jensen RH, Sinclair AJ. European headache federation guideline on idiopathic intracranial hypertension. J Headache Pain 2018;19:93.
- 5. Liamis G, Milionis HJ, Elisaf M. Pharmacologically-induced metabolic acidosis: A review. Drug Saf 2010;33:371–91. [CrossRef]
- 6. Bolay H, Gül A, Baykan B. COVID-19 is a real headache! Headache 2020;60:1415–21. [CrossRef]
- 7. Monteiro ML, Afonso CL. Macular thickness measurements with frequency domain-OCT for quantification of axonal loss in chronic papilledema from pseudotumor cerebri syndrome. Eye (Lond) 2014;28:390–8. [CrossRef]
- 8. Khoo KL, Leng PH, Ibrahim IB, Lim TK. The changing face of healthcare worker perceptions on powered air-purifying respirators during the SARS outbreak. Respirology 2005;10:107–10. [CrossRef]
- 9. Lim EC, Seet RC, Lee KH, Wilder-Smith EP, Chuah BY, Ong BK. Headaches and the N95 face-mask amongst healthcare providers. Acta Neurol Scand 2006;113:199–202. [CrossRef]
- 10. Ekizoglu E, Baykan B, Orhan EK, Ertas M. The analysis of allodynia in patients with idiopathic intracranial hypertension. Cephalalgia 2012;32:1049–58. [CrossRef]
- 11. Mollan SP, Ali F, Hassan-Smith G, Botfield H, Friedman DI, Sinclair AJ. Evolving evidence in adult idiopathic intracranial hypertension: Pathophysiology and management. J Neurol Neurosurg Psychiatry 2016;87:982–92. [CrossRef]
- 12. Altıokka-Uzun G, Tüzün E, Ekizoğlu E, Ulusoy C, Yentür S, Kürtüncü M, et al. Oligoclonal bands and increased cytokine levels in idiopathic intracranial hypertension. Cephalalgia 2015;35:1153–61. [CrossRef]
| APA | gungor tuncer o, Nalbantoglu M, sengul e, Baykan B (2023). Metabolic acidosis during the relapse treatment of idiopathic intracranial hypertension. , 107 - 110. 10.14744/agri.2021.05025 |
| Chicago | gungor tuncer ozlem,Nalbantoglu Mecbure,sengul elvan alper,Baykan Betul Metabolic acidosis during the relapse treatment of idiopathic intracranial hypertension. (2023): 107 - 110. 10.14744/agri.2021.05025 |
| MLA | gungor tuncer ozlem,Nalbantoglu Mecbure,sengul elvan alper,Baykan Betul Metabolic acidosis during the relapse treatment of idiopathic intracranial hypertension. , 2023, ss.107 - 110. 10.14744/agri.2021.05025 |
| AMA | gungor tuncer o,Nalbantoglu M,sengul e,Baykan B Metabolic acidosis during the relapse treatment of idiopathic intracranial hypertension. . 2023; 107 - 110. 10.14744/agri.2021.05025 |
| Vancouver | gungor tuncer o,Nalbantoglu M,sengul e,Baykan B Metabolic acidosis during the relapse treatment of idiopathic intracranial hypertension. . 2023; 107 - 110. 10.14744/agri.2021.05025 |
| IEEE | gungor tuncer o,Nalbantoglu M,sengul e,Baykan B "Metabolic acidosis during the relapse treatment of idiopathic intracranial hypertension." , ss.107 - 110, 2023. 10.14744/agri.2021.05025 |
| ISNAD | gungor tuncer, ozlem vd. "Metabolic acidosis during the relapse treatment of idiopathic intracranial hypertension". (2023), 107-110. https://doi.org/10.14744/agri.2021.05025 |
| APA | gungor tuncer o, Nalbantoglu M, sengul e, Baykan B (2023). Metabolic acidosis during the relapse treatment of idiopathic intracranial hypertension. Ağrı, 25(2), 107 - 110. 10.14744/agri.2021.05025 |
| Chicago | gungor tuncer ozlem,Nalbantoglu Mecbure,sengul elvan alper,Baykan Betul Metabolic acidosis during the relapse treatment of idiopathic intracranial hypertension. Ağrı 25, no.2 (2023): 107 - 110. 10.14744/agri.2021.05025 |
| MLA | gungor tuncer ozlem,Nalbantoglu Mecbure,sengul elvan alper,Baykan Betul Metabolic acidosis during the relapse treatment of idiopathic intracranial hypertension. Ağrı, vol.25, no.2, 2023, ss.107 - 110. 10.14744/agri.2021.05025 |
| AMA | gungor tuncer o,Nalbantoglu M,sengul e,Baykan B Metabolic acidosis during the relapse treatment of idiopathic intracranial hypertension. Ağrı. 2023; 25(2): 107 - 110. 10.14744/agri.2021.05025 |
| Vancouver | gungor tuncer o,Nalbantoglu M,sengul e,Baykan B Metabolic acidosis during the relapse treatment of idiopathic intracranial hypertension. Ağrı. 2023; 25(2): 107 - 110. 10.14744/agri.2021.05025 |
| IEEE | gungor tuncer o,Nalbantoglu M,sengul e,Baykan B "Metabolic acidosis during the relapse treatment of idiopathic intracranial hypertension." Ağrı, 25, ss.107 - 110, 2023. 10.14744/agri.2021.05025 |
| ISNAD | gungor tuncer, ozlem vd. "Metabolic acidosis during the relapse treatment of idiopathic intracranial hypertension". Ağrı 25/2 (2023), 107-110. https://doi.org/10.14744/agri.2021.05025 |
